Eli Lilly & Co

Health Care
Biotechnology: Pharmaceutical Preparations
www.lilly.com

Earnings Score
Moat Score
Safety Score

Market Cap $696.80B
PE 63
Debt $38.52B
Cash $3.09B
EV $732.22B
FCF $3.74B

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$11.11B
EBIT	$13.60B
ROE	70%
ROA	15%
FCF	$3.74B
Equity	$15.85B
Growth Stability	87%
PE	62.74
PEG	6.81
PB	43.97
P/FCF	186.48
P/S	14.22
Price/Cash	0
Debt/Equity	2.43
Debt/FCF	10.31
Net Margins	22%
Gross Margins	82%
Op. Margins	28%
Earnings CAGR	18%
Sales Growth YoY	45%
Sales Growth QoQ	-6%
Sales CAGR	8%
FCF CAGR	-6%
Equity CAGR	-2%
Earnings Stability	0.44
Earnings Growth YoY	23%
Earnings Growth QoQ	-37%
Earnings CAGR 5Y	9%

Sales CAGR 5Y	14%
FCF CAGR 5Y	-28%
Equity CAGR 5Y	26%
Earnings CAGR 3Y	22%
Sales CAGR 3Y	22%
FCF CAGR 3Y	-39%
Equity CAGR 3Y	20%
Market Cap	$696.80B
Revenue	$49.00B
Dividend Yield	1%
Payout Ratio	44%
Assets	$89.39B
Total Debt	$38.52B
Cash	$3.09B
Shares Outstanding	898.7M
EV	732.22B
Earnings Score	53%
Moat Score	96%
Safety Score	69%
Final Score	73%
Working Capital	11.19B
Current Ratio	1.37
Gross Profit	$40.03B
Shares Growth 3y	-0%
Equity Growth QoQ	11%
Equity Growth YoY	23%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer.

SEC Filings

Direct access to Eli Lilly & Co (LLY) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Eli Lilly & Co compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Eli Lilly & Co compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 18%

Stability 44%

loading chart...

Eli Lilly & Co Discounted Cash Flow

Fully customizable DCF calculator online for Eli Lilly & Co.

Years

Calculation mode

= $25B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$3.7B	$3.5B	$3.3B	$3.1B	$2.9B	$2.7B	$2.6B	$2.4B	$2.3B	$2.1B	$2B	$20B
DCF		$3.2B	$2.7B	$2.3B	$2B	$1.7B	$1.5B	$1.2B	$1.1B	$906M	$774M	$7.7B
Value	$25B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	12%	13%	-1%	13%	37%	25%	20%	22%	15%	24%	22%
ROA	-	9%	5%	9%	13%	16%	13%	14%	10%	16%	15%
ROE	-	19%	-2%	30%	308%	106%	61%	58%	48%	74%	70%

Good Net Margins (21.68%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	2.87	3.01	2.96	4.03	3.25	3.07	3.12	32.82	9.2	10.31
Debt over Equity	0.55	0.78	1.17	1.17	5.67	2.85	2	1.51	2.39	2.42	2.43
Growth Stability	-	-	-	100%	100%	100%	94%	93%	87%	100%	87%

Bad Debt/FCF ratio (10.31)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Bad Debt/Equity ratio (2.43)

The company is overleveraged and has a bad balance between equity and debt.

Neutral Graham’s Stability (87%)

The company has a stability in its earnings that is not too good nor too bad.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	6%	8%	7%	-9%	10%	15%	1%	20%	32%	14%
Earnings YoY growth	-	14%	-107%	-2K%	157%	-26%	-10%	12%	-16%	102%	9%
Equity YoY growth	-	-3%	-17%	-7%	-75%	116%	57%	18%	1%	31%	26%
FCF YoY growth	-	123%	19%	-5%	-12%	34%	16%	-12%	-85%	374%	-28%